However, if DCLK1-IN-1 is to be developed further as an RCC-targeted therapy, there is a need for a thorough assessment of its potential nephrotoxicity, the lack of which, is a shortcoming of our current work. This evidence concerns the gene DCLK1 and renal cell carcinoma.